Home LiteratureArticle Details
PMID: 8834867 Published · ppublish English Journal Article Review

Antifungal agents: chemotherapeutic targets and immunologic strategies.

Antimicrobial agents and chemotherapy ·Vol. 40 ·No. 2 ·1996-02-00 ·Pages 279-91

Georgopapadakou NH, Walsh TJ

Abstract

暂无摘要

MeSH Terms
Antifungal Agents/immunology,pharmacology Fungi/drug effects Humans Mycoses/drug therapy
Chemicals
Antifungal Agents
Authors & Affiliations
2 authors, click to expand affiliations / ORCID
Georgopapadakou N H
Department of Oncology, Roche Research Center, Nutley, New Jersey 07110, USA.
Walsh T J
References (262)
262 references, click to expand
  1. Role of yeast elongation factor 3 in the elongation cycle.
    J Biol Chem. 1989 Sep 15;264(26):15423-8 PMID: 2670939
  2. Regulation of the mevalonate pathway.
    Nature. 1990 Feb 1;343(6257):425-30 PMID: 1967820
  3. Mutation in cytochrome P-450-dependent 14 alpha-demethylase results in decreased affinity for azole antifungals.
    Biochem Soc Trans. 1990 Feb;18(1):56-9 PMID: 2185088
  4. Mode of action of 5-fluorocytosine.
    Biochem Pharmacol. 1978 Mar 1;27(5):703-7 PMID: 350227
  5. Ornithine decarboxylase in Pneumocystis carinii and implications for therapy.
    Antimicrob Agents Chemother. 1994 Nov;38(11):2545-52 PMID: 7872745
  6. Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980-1990. National Nosocomial Infections Surveillance System.
    J Infect Dis. 1993 May;167(5):1247-51 PMID: 8486965
  7. Feedback controls and G2 checkpoints: fission yeast as a model system.
    Bioessays. 1993 Dec;15(12):775-82 PMID: 8141795
  8. A high throughput in vitro assay for fungal (1,3)beta-glucan synthase inhibitors.
    J Antibiot (Tokyo). 1994 Sep;47(9):1001-9 PMID: 7928688
  9. Isolation of a chitin synthase gene (CHS1) from Candida albicans by expression in Saccharomyces cerevisiae.
    Mol Microbiol. 1990 Feb;4(2):197-207 PMID: 2140148
  10. The function of chitin synthases 2 and 3 in the Saccharomyces cerevisiae cell cycle.
    J Cell Biol. 1991 Jul;114(1):111-23 PMID: 2050738
  11. Genetics and molecular biology of chitin synthesis in fungi.
    Annu Rev Microbiol. 1993;47:505-34 PMID: 8257107
  12. Isolation and characterization of fluoropyrimidine-resistant mutants in two Candida species.
    Ann N Y Acad Sci. 1988;544:260-3 PMID: 3063172
  13. Cloning and sequence analysis of a Candida maltosa gene which confers resistance to cycloheximide.
    Gene. 1992 Jul 1;116(1):105-8 PMID: 1628836
  14. A Saccharomyces cerevisiae mutant with echinocandin-resistant 1,3-beta-D-glucan synthase.
    J Bacteriol. 1994 Sep;176(18):5686-96 PMID: 8083161
  15. Overview of medically important antifungal azole derivatives.
    Clin Microbiol Rev. 1988 Apr;1(2):187-217 PMID: 3069196
  16. Fungal plasma membrane proton pumps as promising new antifungal targets.
    Crit Rev Microbiol. 1994;20(3):209-23 PMID: 7802957
  17. Comparison of myristoyl-CoA:protein N-myristoyltransferases from three pathogenic fungi: Cryptococcus neoformans, Histoplasma capsulatum, and Candida albicans.
    J Biol Chem. 1994 Jan 28;269(4):2996-3009 PMID: 8300631
  18. Inhibition of sterol biosynthesis enzymes in vitro by analogues of high-energy carbocationic intermediates.
    Biochem Soc Trans. 1990 Feb;18(1):48-52 PMID: 2185086
  19. Sequence analysis of the translational elongation factor 3 from Saccharomyces cerevisiae.
    J Biol Chem. 1990 Feb 5;265(4):1903-12 PMID: 2404974
  20. Cloning of the chitin synthase 3 gene from Candida albicans and its expression during yeast-hyphal transition.
    Mol Gen Genet. 1993 Nov;241(3-4):351-8 PMID: 8246889
  21. Failure of fluconazole treatment in cryptococcal meningitis despite adequate CSF levels.
    J Infect. 1991 Jul;23(1):101-3 PMID: 1885907
  22. In-vitro effect of itraconazole, ketoconazole and amphotericin B on the phagocytic and candidacidal function of human neutrophils.
    J Antimicrob Chemother. 1986 Jul;18(1):83-91 PMID: 3019981
  23. Characterization of the ATPase and GTPase activities of elongation factor 3 (EF-3) purified from yeasts.
    J Biochem. 1988 Mar;103(3):522-30 PMID: 2839469
  24. Targeted gene replacement demonstrates that myristoyl-CoA: protein N-myristoyltransferase is essential for viability of Cryptococcus neoformans.
    Proc Natl Acad Sci U S A. 1994 Dec 6;91(25):12008-12 PMID: 7991574
  25. Two mechanisms of butenafine action in Candida albicans.
    Antimicrob Agents Chemother. 1993 Apr;37(4):785-8 PMID: 8494375
  26. Polyoxin D inhibits growth of zoopathogenic fungi.
    Antimicrob Agents Chemother. 1983 Jun;23(6):926-9 PMID: 6351734
  27. Involvement of calcium, calmodulin and protein phosphorylation in morphogenesis of Candida albicans.
    J Gen Microbiol. 1990 Nov;136(11):2149-54 PMID: 2079619
  28. Cloning and disruption of the yeast C-8 sterol isomerase gene.
    Lipids. 1991 Aug;26(8):628-32 PMID: 1779709
  29. Susceptibility of melanized and nonmelanized Cryptococcus neoformans to nitrogen- and oxygen-derived oxidants.
    Infect Immun. 1994 Jul;62(7):3004-7 PMID: 8005689
  30. Antibodies elicited by a Cryptococcus neoformans-tetanus toxoid conjugate vaccine have the same specificity as those elicited in infection.
    J Infect Dis. 1992 Jun;165(6):1086-93 PMID: 1583327
  31. Nature and development of phenotypic resistance to amphotericin B in Candida albicans.
    Adv Microb Physiol. 1986;27:277-320 PMID: 3532717
  32. Biosynthesis of the yeast cell wall. I. Preparation and properties of beta-(1 leads to 3)glucan synthetase.
    J Biol Chem. 1980 Feb 10;255(3):888-94 PMID: 6766139
  33. Inhibition of 2,3-oxidosqualene cyclases.
    Biochemistry. 1992 Sep 1;31(34):7892-8 PMID: 1510977
  34. Fluconazole combined with flucytosine for treatment of cryptococcal meningitis in patients with AIDS.
    Clin Infect Dis. 1994 Oct;19(4):741-5 PMID: 7803641
  35. Mode of action and resistance to azole antifungals associated with the formation of 14 alpha-methylergosta-8,24(28)-dien-3 beta,6 alpha-diol.
    Biochem Biophys Res Commun. 1995 Feb 27;207(3):910-5 PMID: 7864896
  36. Cryptococcus neoformans serotype A glucuronoxylomannan-protein conjugate vaccines: synthesis, characterization, and immunogenicity.
    Infect Immun. 1991 Oct;59(10):3700-7 PMID: 1716613
  37. A synthetic lethal screen identifies SLK1, a novel protein kinase homolog implicated in yeast cell morphogenesis and cell growth.
    Mol Cell Biol. 1992 Mar;12(3):1162-78 PMID: 1545797
  38. Characterization and cilofungin inhibition of solubilized Aspergillus fumigatus (1,3)-beta-D-glucan synthase.
    Antimicrob Agents Chemother. 1994 May;38(5):937-44 PMID: 8067773
  39. Regulation of fungal cell wall growth: a guanine nucleotide-binding, proteinaceous component required for activity of (1----3)-beta-D-glucan synthase.
    Proc Natl Acad Sci U S A. 1986 Aug;83(16):5808-12 PMID: 2942941
  40. Comparative and collaborative evaluation of standardization of antifungal susceptibility testing for filamentous fungi.
    Antimicrob Agents Chemother. 1995 Feb;39(2):314-9 PMID: 7726488
  41. Synthesis and antifungal activity of novel cationic pneumocandin B(o) derivatives.
    J Med Chem. 1994 Jan 21;37(2):222-5 PMID: 8295208
  42. Pathogenicity determinants of Candida albicans: potential targets for immunotherapy?
    Microbiology. 1994 Jul;140 ( Pt 7):1505-11 PMID: 8075793
  43. Investigation of the role of sterol delta 8-->7-isomerase in the sensitivity of Saccharomyces cerevisiae to fenpropimorph.
    FEMS Microbiol Lett. 1994 Oct 1;122(3):223-6 PMID: 7988864
  44. Genetics and biochemistry of yeast multidrug resistance.
    Biochim Biophys Acta. 1994 Aug 30;1187(2):152-62 PMID: 8075109
  45. Treatment of Pneumocystis carinii pneumonia with 1,3-beta-glucan synthesis inhibitors.
    Proc Natl Acad Sci U S A. 1990 Aug;87(15):5950-4 PMID: 2198575
  46. New antifungal antibiotics, benanomicins A and B from an actinomycete.
    J Antibiot (Tokyo). 1988 Jun;41(6):807-11 PMID: 3403377
  47. Review: cell wall assembly in yeast.
    Yeast. 1994 Jul;10(7):851-69 PMID: 7985414
  48. Incidence of polyene-resistant yeasts recovered from clinical specimens.
    Antimicrob Agents Chemother. 1980 Jul;18(1):158-63 PMID: 7416742
  49. Is there a role for GPIs in yeast cell-wall assembly?
    Trends Cell Biol. 1994 Feb;4(2):42-5 PMID: 14731865
  50. DNA topoisomerase poisons as antitumor drugs.
    Annu Rev Biochem. 1989;58:351-75 PMID: 2549853
  51. Melanized and non-melanized multicellular form mutants of Wangiella dermatitidis in mice: mortality and histopathology studies.
    Mycoses. 1992 Jan-Feb;35(1-2):17-21 PMID: 1406785
  52. Evolving role of flucytosine in immunocompromised patients: new insights into safety, pharmacokinetics, and antifungal therapy.
    Clin Infect Dis. 1992 Dec;15(6):1003-18 PMID: 1457631
  53. Sensitivity to nikkomycin Z in Candida albicans: role of peptide permeases.
    J Bacteriol. 1984 Dec;160(3):884-8 PMID: 6389515
  54. Scanning electron microscopy of epidermal adherence and cavitation in murine candidiasis: a role for Candida acid proteinase.
    Infect Immun. 1988 Aug;56(8):1942-9 PMID: 3294180
  55. The gene encoding phosphoribosylaminoimidazole carboxylase (ADE2) is essential for growth of Cryptococcus neoformans in cerebrospinal fluid.
    Infect Immun. 1993 Oct;61(10):4446-51 PMID: 8406836
  56. Resistance of Candida species to fluconazole.
    Antimicrob Agents Chemother. 1995 Jan;39(1):1-8 PMID: 7695288
  57. Eukaryotic protein synthesis.
    Annu Rev Biochem. 1985;54:1109-49 PMID: 3896117
  58. Action of antifungal imidazoles on Staphylococcus aureus.
    Antimicrob Agents Chemother. 1982 Sep;22(3):470-4 PMID: 6291453
  59. Biochemical studies with a novel antifungal agent, ICI 195,739.
    Ann N Y Acad Sci. 1988;544:231-44 PMID: 3063170
  60. Treatment of experimental invasive aspergillosis with novel amphotericin B/cholesterol-sulfate complexes.
    J Infect Dis. 1989 Apr;159(4):717-24 PMID: 2926162
  61. Nikkomycin Z is a specific inhibitor of Saccharomyces cerevisiae chitin synthase isozyme Chs3 in vitro and in vivo.
    J Bacteriol. 1994 Sep;176(18):5857-60 PMID: 8083179
  62. In vitro and in vivo antifungal activities of BMS-181184.
    J Antibiot (Tokyo). 1992 Sep;45(9):1512-7 PMID: 1429237
  63. Adherence and receptor relationships of Candida albicans.
    Microbiol Rev. 1991 Mar;55(1):1-20 PMID: 2030668
  64. Chitinase and chitin synthase 1: counterbalancing activities in cell separation of Saccharomyces cerevisiae.
    J Gen Microbiol. 1992 Jan;138(1):97-102 PMID: 1556560
  65. Efficacy of amphotericin B encapsulated in liposomes (AmBisome) in the treatment of invasive fungal infections in immunocompromised patients.
    J Antimicrob Chemother. 1991 Oct;28 Suppl B:73-82 PMID: 1778894
  66. In vivo interferon-gamma therapy augments the in vitro ability of chronic granulomatous disease neutrophils to damage Aspergillus hyphae.
    J Infect Dis. 1991 Apr;163(4):849-52 PMID: 1901332
  67. A receptor-mediated pathway for cholesterol homeostasis.
    Science. 1986 Apr 4;232(4746):34-47 PMID: 3513311
  68. Amphotericin B-resistant yeast infection in severely immunocompromised patients.
    Am J Med. 1988 May;84(5):826-32 PMID: 3284339
  69. Resistance to amphotericin B associated with defective sterol delta 8-->7 isomerase in a Cryptococcus neoformans strain from an AIDS patient.
    FEMS Microbiol Lett. 1994 Sep 15;122(1-2):39-42 PMID: 7958776
  70. Critical steps in fungal cell wall synthesis: strategies for their inhibition.
    Pharmacol Ther. 1993 Nov;60(2):337-45 PMID: 8022864
  71. Pneumocystis carinii is resistant to imidazole antifungal agents.
    Antimicrob Agents Chemother. 1994 Aug;38(8):1859-61 PMID: 7986021
  72. Strain delineation and antifungal susceptibilities of epidemiologically related and unrelated isolates of Candida lusitaniae.
    Diagn Microbiol Infect Dis. 1994 Nov;20(3):127-33 PMID: 7874879
  73. The phosphoinositol sphingolipids of Saccharomyces cerevisiae are highly localized in the plasma membrane.
    J Bacteriol. 1991 May;173(10):3101-8 PMID: 1827112
  74. Cytochrome P-450-dependent 14 alpha-sterol demethylase of Candida albicans and its interaction with azole antifungals.
    Biochem Soc Trans. 1991 Aug;19(3):782-7 PMID: 1783216
  75. Positive interaction of nikkomycins and azoles against Candida albicans in vitro and in vivo.
    Antimicrob Agents Chemother. 1992 Jun;36(6):1284-9 PMID: 1416829
  76. DNA topoisomerases from pathogenic fungi: targets for the discovery of antifungal drugs.
    Antimicrob Agents Chemother. 1992 Dec;36(12):2778-84 PMID: 1336349
  77. Impact of the changing epidemiology of fungal infections in the 1990s.
    Eur J Clin Microbiol Infect Dis. 1992 Apr;11(4):287-91 PMID: 1396747
  78. Nosocomial fungal infections: a classification for hospital-acquired fungal infections and mycoses arising from endogenous flora or reactivation.
    Annu Rev Microbiol. 1988;42:517-45 PMID: 3060000
  79. Phase I trial of recombinant human macrophage colony-stimulating factor in patients with invasive fungal infections.
    Blood. 1991 Aug 15;78(4):907-13 PMID: 1868251
  80. Empiric treatment of fungal infections in the neutropenic host. Review of the literature and guidelines for use.
    Arch Intern Med. 1990 Nov;150(11):2258-64 PMID: 2241435
  81. The fibronectin adhesin of Candida albicans.
    Infect Immun. 1994 Oct;62(10):4679-81 PMID: 7927741
  82. The 14th C. L. Oakley Lecture. Candida albicans HSP 90: link between protective and auto immunity.
    J Med Microbiol. 1992 Jun;36(6):367-70 PMID: 1377277
  83. Use of cilofungin as direct fluorescent probe for monitoring antifungal drug-membrane interaction.
    Antimicrob Agents Chemother. 1994 Jun;38(6):1378-85 PMID: 8092841
  84. Molecular cloning and characterization of chitinase genes from Candida albicans.
    Proc Natl Acad Sci U S A. 1995 Mar 28;92(7):2544-8 PMID: 7708682
  85. Epidemiology and pathogenesis of systemic fungal infections in the immunocompromised host.
    J Antimicrob Chemother. 1991 Oct;28 Suppl B:1-16 PMID: 1778886
  86. Characterization of an azole-resistant Candida glabrata isolate.
    Antimicrob Agents Chemother. 1992 Dec;36(12):2602-10 PMID: 1482129
  87. Polyamine depletion and growth inhibition of Cryptococcus neoformans by alpha-difluoromethylornithine and cyclohexylamine.
    Mycopathologia. 1990 Oct;112(1):27-32 PMID: 2250691
  88. Comparison of the acyl chain specificities of human myristoyl-CoA synthetase and human myristoyl-CoA:protein N-myristoyltransferase.
    J Biol Chem. 1993 Mar 5;268(7):4889-902 PMID: 8444867
  89. A candidate protein kinase C gene, PKC1, is required for the S. cerevisiae cell cycle.
    Cell. 1990 Jul 27;62(2):213-24 PMID: 2196995
  90. Calcium-dependent anticandidal action of pradimicin A.
    J Antibiot (Tokyo). 1990 Jun;43(6):715-21 PMID: 2199421
  91. Chitin synthase 2 is essential for septum formation and cell division in Saccharomyces cerevisiae.
    Proc Natl Acad Sci U S A. 1988 Jul;85(13):4735-9 PMID: 2968606
  92. Ornithine decarboxylase as an enzyme target for therapy.
    Pharmacol Ther. 1992;54(2):195-215 PMID: 1438532
  93. Antimitotic agents: chemistry and recognition of tubulin molecule.
    Med Res Rev. 1993 Mar;13(2):183-98 PMID: 8445957
  94. Defective sterol C5-6 desaturation and azole resistance: a new hypothesis for the mode of action of azole antifungals.
    Biochem Biophys Res Commun. 1989 Nov 15;164(3):1170-5 PMID: 2556119
  95. Lipid composition and polyene antibiotic resistance of Candida albicans mutants.
    Can J Biochem. 1978 Feb;56(2):135-42 PMID: 343892
  96. A yeast mitogen-activated protein kinase homolog (Mpk1p) mediates signalling by protein kinase C.
    Mol Cell Biol. 1993 May;13(5):3067-75 PMID: 8386319
  97. Structure-activity and structure-selectivity studies on diaminoquinazolines and other inhibitors of Pneumocystis carinii and Toxoplasma gondii dihydrofolate reductase.
    Antimicrob Agents Chemother. 1995 Jan;39(1):79-86 PMID: 7695334
  98. Sterol biosynthesis inhibitors: their current status and modes of action.
    Lipids. 1991 Aug;26(8):584-97 PMID: 1779706
  99. A GTP-binding protein regulates the activity of (1-->3)-beta-glucan synthase, an enzyme directly involved in yeast cell wall morphogenesis.
    J Biol Chem. 1994 Dec 9;269(49):31267-74 PMID: 7983071
  100. Anti-Candida activity of cispentacin: the active transport by amino acid permeases and possible mechanisms of action.
    Biochem Biophys Res Commun. 1993 Feb 15;190(3):1037-44 PMID: 8439305
  101. Resistance of Candida albicans to azole antifungal agents.
    Biochem Soc Trans. 1993 Nov;21(4):1039-47 PMID: 8131894
  102. Alfred P. Sloan, Jr. Prize. Role of yeast in cancer research.
    Cancer. 1992 May 15;69(10):2615-21 PMID: 1568186
  103. Distinct mechanisms of epithelial adhesion for Candida albicans and Candida tropicalis. Identification of the participating ligands and development of inhibitory peptides.
    J Clin Invest. 1993 Oct;92(4):1840-9 PMID: 8408636
  104. Management of fever in patients with cancer and treatment-induced neutropenia.
    N Engl J Med. 1993 May 6;328(18):1323-32 PMID: 8469254
  105. Resistance of yeasts to azole-derivative antifungals.
    J Antimicrob Chemother. 1993 Apr;31(4):463-71 PMID: 8514644
  106. Flucytosine--what is its future?
    J Antimicrob Chemother. 1995 Feb;35(2):241-4 PMID: 7759388
  107. G1 phase progression: cycling on cue.
    Cell. 1994 Nov 18;79(4):551-5 PMID: 7954821
  108. Construction and growth properties of a yeast strain defective in sterol 14-reductase.
    Curr Genet. 1992 Oct;22(4):267-72 PMID: 1394506
  109. Mechanism of action of nikkomycin and the peptide transport system of Candida albicans.
    J Gen Microbiol. 1985 Apr;131(4):775-80 PMID: 3886837
  110. Purification of yeast tubulin by self-assembly in vitro.
    Biochemistry. 1981 Jun 9;20(12):3629-33 PMID: 7020758
  111. The preparation of zaragozic acid A analogues by directed biosynthesis.
    J Antibiot (Tokyo). 1994 Nov;47(11):1290-4 PMID: 8002393
  112. Comparison of antifungal activity of amphotericin B deoxycholate suspension with that of amphotericin B cholesteryl sulfate colloidal dispersion.
    Antimicrob Agents Chemother. 1992 Feb;36(2):486-8 PMID: 1605618
  113. Effects of azole antifungals in vitro on host/parasite interactions relevant to Candida infections.
    J Antimicrob Chemother. 1988 Oct;22(4):473-81 PMID: 2849601
  114. Effects of naftifine and terbinafine, two allylamine antifungal drugs, on selected functions of human polymorphonuclear leukocytes.
    Antimicrob Agents Chemother. 1994 Nov;38(11):2605-11 PMID: 7872755
  115. Amphotericins A and B, antifungal antibiotics produced by a streptomycete. I. In vitro studies.
    Antibiot Annu. 1955-1956;3:579-86 PMID: 13355330
  116. Effect of antifungal agents on lipid biosynthesis and membrane integrity in Candida albicans.
    Antimicrob Agents Chemother. 1987 Jan;31(1):46-51 PMID: 3551826
  117. The squalestatins, novel inhibitors of squalene synthase produced by a species of Phoma. I. Taxonomy, fermentation, isolation, physico-chemical properties and biological activity.
    J Antibiot (Tokyo). 1992 May;45(5):639-47 PMID: 1624366
  118. Transfer of protective immunity in murine histoplasmosis by a CD4+ T-cell clone.
    Infect Immun. 1993 Feb;61(2):714-8 PMID: 8093695
  119. Inhibitors of sterol biosynthesis and their applications.
    Prog Lipid Res. 1993;32(4):357-416 PMID: 8309949
  120. A role for complement receptor-like molecules in iron acquisition by Candida albicans.
    J Exp Med. 1992 Jun 1;175(6):1643-51 PMID: 1588285
  121. In-vitro effects of liposome-encapsulated amphotericin B (AmBisome) and amphotericin B-deoxycholate (Fungizone) on the phagocytic and candidacidal function of human polymorphonuclear leucocytes.
    J Antimicrob Chemother. 1992 Sep;30(3):313-20 PMID: 1452496
  122. Sphingofungins E and F: novel serinepalmitoyl transferase inhibitors from Paecilomyces variotii.
    J Antibiot (Tokyo). 1992 Oct;45(10):1692-6 PMID: 1474000
  123. Treatment of systemic fungal infections with liposomal amphotericin B.
    Arch Intern Med. 1989 Nov;149(11):2533-6 PMID: 2818111
  124. Biochemical targets for antifungal azole derivatives: hypothesis on the mode of action.
    Curr Top Med Mycol. 1985;1:313-51 PMID: 3916772
  125. Cispentacin, a new antifungal antibiotic. II. In vitro and in vivo antifungal activities.
    J Antibiot (Tokyo). 1989 Dec;42(12):1756-62 PMID: 2621158
  126. Complementation of a capsule-deficient mutation of Cryptococcus neoformans restores its virulence.
    Mol Cell Biol. 1994 Jul;14(7):4912-9 PMID: 8007987
  127. Emergence of Candida krusei infections after therapy of oropharyngeal candidiasis with fluconazole.
    Eur J Clin Microbiol Infect Dis. 1991 Jul;10(7):598-9 PMID: 1915408
  128. Dissimilarity in protein chain elongation factor requirements between yeast and rat liver ribosomes.
    J Biol Chem. 1977 Feb 25;252(4):1471-5 PMID: 320208
  129. Therapeutic efficacy of monoclonal antibodies to Cryptococcus neoformans glucuronoxylomannan alone and in combination with amphotericin B.
    Antimicrob Agents Chemother. 1994 Mar;38(3):580-7 PMID: 8203858
  130. Correlation between in vitro and in vivo activity of antifungal agents against Candida species.
    J Infect Dis. 1994 Aug;170(2):384-9 PMID: 8035024
  131. Antimicrobial susceptibility of Pneumocystis carinii in culture.
    Diagn Microbiol Infect Dis. 1985 Sep;3(5):381-7 PMID: 3875445
  132. Lysis of growing yeast-form cells of Candida albicans by echinocandin: a cytological study.
    Sabouraudia. 1981 Jun;19(2):97-110 PMID: 7020114
  133. Prevention of corticosteroid-induced suppression of human polymorphonuclear leukocyte-induced damage of Aspergillus fumigatus hyphae by granulocyte colony-stimulating factor and gamma interferon.
    Infect Immun. 1993 Nov;61(11):4870-7 PMID: 7691757
  134. Fungal cell wall synthesis: the construction of a biological structure.
    Microbiol Sci. 1988 Dec;5(12):370-5 PMID: 3079180
  135. Cloning and sequence of a beta-tubulin cDNA from Pneumocystis carinii: possible implications for drug therapy.
    Mol Microbiol. 1992 Apr;6(8):991-1001 PMID: 1584027
  136. Polyamines.
    Annu Rev Biochem. 1984;53:749-90 PMID: 6206782
  137. Amphotericin B causes aggregation of neutrophils and enhances pulmonary leukostasis.
    Am Rev Respir Dis. 1985 Sep;132(3):602-5 PMID: 4037532
  138. Allylamine derivatives: new class of synthetic antifungal agents inhibiting fungal squalene epoxidase.
    Science. 1984 Jun 15;224(4654):1239-41 PMID: 6547247
  139. A conserved kinase cascade for MAP kinase activation in yeast.
    Curr Opin Cell Biol. 1993 Apr;5(2):254-60 PMID: 8389568
  140. Mechanism and inhibition of delta 24-sterol methyltransferase from Candida albicans and Candida tropicalis.
    Biochemistry. 1989 Dec 12;28(25):9633-40 PMID: 2692713
  141. Saccharomyces cerevisiae mutant with a partial defect in the synthesis of CDP-diacylglycerol and altered regulation of phospholipid biosynthesis.
    J Bacteriol. 1988 Apr;170(4):1878-86 PMID: 2832385
  142. Effects of antifungal agents on the function of human neutrophils in vitro.
    Antimicrob Agents Chemother. 1990 Feb;34(2):196-201 PMID: 2158275
  143. Effect of an arginine-glycine-aspartic acid-containing peptide on hematogenous candidal infections in rabbits.
    Antimicrob Agents Chemother. 1992 Jan;36(1):132-6 PMID: 1590678
  144. Evaluation of the protective efficacy of the killed Coccidioides immitis spherule vaccine in humans. The Valley Fever Vaccine Study Group.
    Am Rev Respir Dis. 1993 Sep;148(3):656-60 PMID: 8368636
  145. Fluconazole and testosterone: in vivo and in vitro studies.
    Antimicrob Agents Chemother. 1988 May;32(5):646-8 PMID: 2840013
  146. Neutralization of IL-10 up-regulates nitric oxide production and protects susceptible mice from challenge with Candida albicans.
    J Immunol. 1994 Apr 1;152(7):3514-21 PMID: 7908304
  147. The collagen binding domain of fibronectin contains a high affinity binding site for Candida albicans.
    J Biol Chem. 1994 Sep 2;269(35):22039-45 PMID: 8071326
  148. Cure of murine candidiasis by recombinant soluble interleukin-4 receptor.
    J Infect Dis. 1994 Jun;169(6):1325-31 PMID: 8195611
  149. Synthesis of the yeast cell wall and its regulation.
    Annu Rev Biochem. 1982;51:763-93 PMID: 7051965
  150. A non-azole inhibitor of lanosterol 14 alpha-methyl demethylase in Candida albicans.
    J Antimicrob Chemother. 1992 Dec;30(6):781-90 PMID: 1289352
  151. The fungal cell wall as a drug target.
    Trends Microbiol. 1995 Mar;3(3):98-104 PMID: 7773595
  152. Mutants in the S. cerevisiae PKC1 gene display a cell cycle-specific osmotic stability defect.
    J Cell Biol. 1992 Mar;116(5):1221-9 PMID: 1740473
  153. Antifungal effects of the nonlinear pharmacokinetics of cilofungin, a 1,3-beta-glucan synthetase inhibitor, during continuous and intermittent intravenous infusions in treatment of experimental disseminated candidiasis.
    Antimicrob Agents Chemother. 1991 Jul;35(7):1321-8 PMID: 1929288
  154. Structure and function of type II DNA topoisomerases.
    Biochem J. 1994 Nov 1;303 ( Pt 3):681-95 PMID: 7980433
  155. Correlation of cilofungin in vivo efficacy with its activity against Aspergillus fumigatus (1,3)-beta-D-glucan synthase.
    FEMS Microbiol Lett. 1993 Apr 1;108(2):133-7 PMID: 8486238
  156. Drug resistance in Candida albicans and Candida glabrata.
    Ann N Y Acad Sci. 1988;544:245-59 PMID: 3063171
  157. Phospholipid biosynthesis in yeast.
    Annu Rev Biochem. 1989;58:635-69 PMID: 2673019
  158. A screening method for antifungal substances using Saccharomyces cerevisiae strains resistant to polyene macrolides.
    J Antibiot (Tokyo). 1990 Feb;43(2):199-206 PMID: 2179187
  159. Molecular basis of Candida albicans adhesion.
    J Med Vet Mycol. 1992;30 Suppl 1:95-122 PMID: 1474465
  160. Putative virulence factors of Candida albicans.
    Annu Rev Microbiol. 1991;45:187-218 PMID: 1741614
  161. Modulation of host defenses by cytokines: evolving adjuncts in prevention and treatment of serious infections in immunocompromised hosts.
    Clin Infect Dis. 1992 Sep;15(3):508-24 PMID: 1520801
  162. Antifungal susceptibility testing.
    Clin Microbiol Rev. 1993 Oct;6(4):367-81 PMID: 8269392
  163. Synthesis and evaluation of LY121019, a member of a series of semisynthetic analogues of the antifungal lipopeptide echinocandin B.
    Ann N Y Acad Sci. 1988;544:152-67 PMID: 3063167
  164. Novel aspect of amphotericin B action: accumulation in human monocytes potentiates killing of phagocytosed Candida albicans.
    Antimicrob Agents Chemother. 1994 Jan;38(1):13-22 PMID: 8141565
  165. Studies on the mode of antifungal action of pradimicin antibiotics. II. D-mannopyranoside-binding site and calcium-binding site.
    J Antibiot (Tokyo). 1993 Mar;46(3):455-64 PMID: 8478263
  166. Protective and nonprotective monoclonal antibodies to Cryptococcus neoformans originating from one B cell.
    J Exp Med. 1995 Jan 1;181(1):405-9 PMID: 7807020
  167. Adhesins and ligands involved in the interaction of Candida spp. with epithelial and endothelial surfaces.
    Clin Microbiol Rev. 1994 Jan;7(1):29-42 PMID: 8118789
  168. Characterization of a novel, potent, and specific inhibitor of serine palmitoyltransferase.
    J Biol Chem. 1992 Dec 15;267(35):25032-8 PMID: 1460005
  169. Disruption of the yeast N-myristoyl transferase gene causes recessive lethality.
    Science. 1989 Feb 10;243(4892):796-800 PMID: 2644694
  170. Nystatin-resistant mutants of yeast: alterations in sterol content.
    J Bacteriol. 1971 Oct;108(1):69-73 PMID: 5122815
  171. Fusarium-caused hyalohyphomycosis: an overview.
    Curr Top Med Mycol. 1992;4:231-49 PMID: 1732068
  172. 4-oxatetradecanoic acid is fungicidal for Cryptococcus neoformans and inhibits replication of human immunodeficiency virus I.
    J Biol Chem. 1992 Aug 25;267(24):17159-69 PMID: 1512254
  173. The mechanism of antifungal action of (S)-2-amino-4-oxo-5-hydroxypentanoic acid, RI-331: the inhibition of homoserine dehydrogenase in Saccharomyces cerevisiae.
    Biochem Biophys Res Commun. 1990 Apr 30;168(2):837-43 PMID: 1970730
  174. Papulacandin B: an inhibitor of glucan synthesis in yeast spheroplasts.
    Eur J Biochem. 1979 Jul;97(2):345-51 PMID: 380990
  175. Identification of antigens of Coccidioides immitis which stimulated immune T lymphocytes.
    Arch Med Res. 1993 Autumn;24(3):281-91 PMID: 8298279
  176. ABC transporters: from microorganisms to man.
    Annu Rev Cell Biol. 1992;8:67-113 PMID: 1282354
  177. The lipid composition and permeability to azole of an azole- and polyene-resistant mutant of Candida albicans.
    J Med Vet Mycol. 1987 Feb;25(1):29-37 PMID: 3553525
  178. Cytokines in the pathogenesis and treatment of infectious diseases.
    Adv Pediatr Infect Dis. 1994;9:211-36 PMID: 7510110
  179. Biochemical changes associated with the antifungal action of the triazole ICI 153,066 on Candida albicans and Trichophyton quinckeanum.
    FEMS Microbiol Lett. 1991 Apr 15;63(2-3):127-31 PMID: 2060756
  180. Pneumocystis carinii pneumonia: new approaches to diagnosis, treatment and prevention.
    Pediatr Infect Dis J. 1991 May;10(5):391-9 PMID: 2067889
  181. Urinary tract infections due to Candida albicans.
    Rev Infect Dis. 1982 Nov-Dec;4(6):1107-18 PMID: 6760338
  182. W-1 solubilization and kinetics of inhibition by cilofungin of Candida albicans (1,3)-beta-D-glucan synthase.
    Antimicrob Agents Chemother. 1991 Jan;35(1):99-103 PMID: 1826595
  183. Problems in the diagnosis of invasive fungal diseases.
    Rev Infect Dis. 1991 May-Jun;13(3):493-5 PMID: 1866555
  184. Conservation between human and fungal squalene synthetases: similarities in structure, function, and regulation.
    Mol Cell Biol. 1993 May;13(5):2706-17 PMID: 8474436
  185. Sphingofungins A, B, C, and D; a new family of antifungal agents. I. Fermentation, isolation, and biological activity.
    J Antibiot (Tokyo). 1992 Jun;45(6):861-7 PMID: 1500351
  186. Nikkomycin Z supersensitivity of an echinocandin-resistant mutant of Saccharomyces cerevisiae.
    Antimicrob Agents Chemother. 1995 Jan;39(1):200-7 PMID: 7695307
  187. The growing problem of mycoses in patients infected with the human immunodeficiency virus.
    Rev Infect Dis. 1991 May-Jun;13(3):480-6 PMID: 1866553
  188. Emergence of azole drug resistance in Candida species from HIV-infected patients receiving prolonged fluconazole therapy for oral candidosis.
    J Antimicrob Chemother. 1995 Jan;35(1):103-14 PMID: 7768758
  189. Novel pentamidine analogs in the treatment of experimental Pneumocystis carinii pneumonia.
    Antimicrob Agents Chemother. 1990 Jun;34(6):1026-30 PMID: 2393262
  190. Candida albicans and three other Candida species contain an elongation factor structurally and functionally analogous to elongation factor 3.
    FEMS Microbiol Lett. 1991 May 1;64(1):45-9 PMID: 1855649
  191. Coccidioidomycosis during human immunodeficiency virus infection: results of a prospective study in a coccidioidal endemic area.
    Am J Med. 1993 Mar;94(3):235-40 PMID: 8095771
  192. Metabolic products of microorganisms. 255. Nikkomycins Wz and Wx, new chitin synthetase inhibitors from Streptomyces tendae.
    J Antibiot (Tokyo). 1990 Jan;43(1):43-8 PMID: 2137814
  193. Biosynthesis of the fungal wall - mechanisms and implications. The first Fleming Lecture.
    J Gen Microbiol. 1977 Mar;99(1):1-11 PMID: 864434
  194. NB-598: a potent competitive inhibitor of squalene epoxidase.
    J Biol Chem. 1990 Oct 25;265(30):18075-8 PMID: 2211682
  195. The prevalence of yeasts in clinical specimens from cancer patients.
    Am J Clin Pathol. 1980 Apr;73(4):518-21 PMID: 7369176
  196. Nosocomial pneumonia in patients having bone marrow transplant. Attributable mortality and risk factors.
    Cancer. 1992 Jun 1;69(11):2653-62 PMID: 1315207
  197. A comparative analysis of the kinetic mechanism and peptide substrate specificity of human and Saccharomyces cerevisiae myristoyl-CoA:protein N-myristoyltransferase.
    J Biol Chem. 1993 May 15;268(14):9964-71 PMID: 8486723
  198. Hematopoietic reconstruction: new approaches.
    Clin Cancer Res. 1995 Jan;1(1):3-9 PMID: 9815881
  199. Fluconazole-resistant recurrent oral candidiasis in human immunodeficiency virus-positive patients: persistence of Candida albicans strains with the same genotype.
    J Clin Microbiol. 1994 Apr;32(4):1115-8 PMID: 8027327
  200. Efficacy of unilamellar liposomal amphotericin B in treatment of pulmonary aspergillosis in persistently granulocytopenic rabbits: the potential role of bronchoalveolar D-mannitol and serum galactomannan as markers of infection.
    J Infect Dis. 1994 Feb;169(2):356-68 PMID: 8106769
  201. Characterization of (1,3)-beta-glucan synthase in Candida albicans: microsomal assay from the yeast or mycelial morphological forms and a permeabilized whole-cell assay.
    Microbiology. 1994 Sep;140 ( Pt 9):2239-46 PMID: 7952175
  202. Squalene epoxidase as a target for the allylamines.
    Biochem Soc Trans. 1991 Aug;19(3):774-7 PMID: 1783214
  203. A secreted beta-glucan-branching enzyme from Candida albicans.
    Proc Biol Sci. 1991 Nov 22;246(1316):155-60 PMID: 1685240
  204. Amphotericin B: current understanding of mechanisms of action.
    Antimicrob Agents Chemother. 1990 Feb;34(2):183-8 PMID: 2183713
  205. Molecular genetic studies on the mode of action of azole antifungal agents.
    Biochem Soc Trans. 1991 Aug;19(3):796-8 PMID: 1783219
  206. Selective inhibition of topoisomerases from Pneumocystis carinii compared with that of topoisomerases from mammalian cells.
    Antimicrob Agents Chemother. 1994 Sep;38(9):1890-8 PMID: 7810995
  207. Genetic and biochemical studies of protein N-myristoylation.
    Annu Rev Biochem. 1994;63:869-914 PMID: 7979256
  208. Failure of fluconazole therapy in Candida krusei fungemia.
    Eur J Clin Microbiol Infect Dis. 1991 Mar;10(3):173 PMID: 2060520
  209. Fungal 1,3-beta-glucan synthase.
    Methods Enzymol. 1987;138:637-42 PMID: 2955197
  210. Phospholipid biosynthesis in Candida albicans: regulation by the precursors inositol and choline.
    J Bacteriol. 1990 Aug;172(8):4407-14 PMID: 2198258
  211. Neutralizing antibody to interleukin 4 induces systemic protection and T helper type 1-associated immunity in murine candidiasis.
    J Exp Med. 1992 Jul 1;176(1):19-25 PMID: 1535368
  212. MKK1 and MKK2, which encode Saccharomyces cerevisiae mitogen-activated protein kinase-kinase homologs, function in the pathway mediated by protein kinase C.
    Mol Cell Biol. 1993 May;13(5):3076-83 PMID: 8386320
  213. Identification of the aminocatechol A-3253 as an in vitro poison of DNA topoisomerase I from Candida albicans.
    Antimicrob Agents Chemother. 1995 Mar;39(3):586-92 PMID: 7793856
  214. Candida albicans gene encoding resistance to benomyl and methotrexate is a multidrug resistance gene.
    Antimicrob Agents Chemother. 1994 Apr;38(4):648-52 PMID: 8031026
  215. Impairment of neutrophil antifungal activity against hyphae of Aspergillus fumigatus in children infected with human immunodeficiency virus.
    J Infect Dis. 1993 Apr;167(4):905-11 PMID: 8450255
  216. Opportunistic and pathogenic fungi.
    J Antimicrob Chemother. 1991 Jul;28 Suppl A:1-11 PMID: 1938702
  217. Mechanism of action and biochemical selectivity of allylamine antimycotic agents.
    Ann N Y Acad Sci. 1988;544:208-20 PMID: 3063168
  218. The structural requirements of sterols for membrane function in Saccharomyces cerevisiae.
    Arch Biochem Biophys. 1993 Feb 1;300(2):724-33 PMID: 8434952
  219. Molecular biology and genetics of tubulin.
    Annu Rev Biochem. 1985;54:331-65 PMID: 3896122
  220. Encapsulation and melanin formation as indicators of virulence in Cryptococcus neoformans.
    Infect Immun. 1986 Jan;51(1):218-23 PMID: 3079732
  221. Susceptibility testing of fungi: current status of the standardization process.
    Antimicrob Agents Chemother. 1993 Dec;37(12):2517-21 PMID: 8109912
  222. Starting to cycle: G1 controls regulating cell division in budding yeast.
    J Gen Microbiol. 1993 Nov;139(11):2531-41 PMID: 8277239
  223. Differential inhibition of chitin synthetases 1 and 2 from Saccharomyces cerevisiae by polyoxin D and nikkomycins.
    Antimicrob Agents Chemother. 1991 Jan;35(1):170-3 PMID: 2014972
  224. Effects of squalene epoxidase inhibitors on Candida albicans.
    Antimicrob Agents Chemother. 1992 Aug;36(8):1779-81 PMID: 1416865
  225. Inhibition of yeast (1,3)-beta-glucan synthase by phospholipase A2 and its reaction products.
    Biochim Biophys Acta. 1994 Jul 13;1193(1):31-40 PMID: 8038192
  226. Extracellular aspartic proteinases from Candida albicans, Candida tropicalis, and Candida parapsilosis yeasts differ substantially in their specificities.
    Biochemistry. 1994 Aug 16;33(32):9791-9 PMID: 8068659
  227. Amphotericin B: 30 years of clinical experience.
    Rev Infect Dis. 1990 Mar-Apr;12(2):308-29 PMID: 2184499
  228. Pradimicin, a novel class of potent antifungal antibiotics.
    J Antibiot (Tokyo). 1988 Nov;41(11):1701-4 PMID: 3198502
  229. Cell extracts of Candida albicans block adherence of the organisms to endothelial cells.
    Infect Immun. 1992 Aug;60(8):3087-91 PMID: 1386347
  230. Evidence implicating phospholipase as a virulence factor of Candida albicans.
    Infect Immun. 1995 May;63(5):1993-8 PMID: 7729913
  231. Cispentacin, a new antifungal antibiotic. I. Production, isolation, physico-chemical properties and structure.
    J Antibiot (Tokyo). 1989 Dec;42(12):1749-55 PMID: 2516082
  232. Analyses of Pneumocystis fatty acids.
    J Protozool. 1989 Jan-Feb;36(1):69S-72S PMID: 2785203
  233. Two chitin synthases in Saccharomyces cerevisiae.
    J Biol Chem. 1987 Apr 25;262(12):5732-9 PMID: 2952643
  234. A second gene for a secreted aspartate proteinase in Candida albicans.
    J Bacteriol. 1992 Dec;174(23):7848-53 PMID: 1447155
  235. An arthroconidial-spherule antigen of Coccidioides immitis: differential expression during in vitro fungal development and evidence for humoral response in humans after infection or vaccination.
    Infect Immun. 1992 Jul;60(7):2627-35 PMID: 1612732
  236. Immunomodulation and antifungal therapy of experimental invasive candidosis, histoplasmosis and aspergillosis: recent advances and concepts.
    J Med Vet Mycol. 1992;30 Suppl 1:225-40 PMID: 1474448
  237. Modulation of interactions of Candida albicans and endothelial cells by fluconazole and amphotericin B.
    Antimicrob Agents Chemother. 1992 Oct;36(10):2239-44 PMID: 1444305
  238. Empiric therapy with amphotericin B in febrile granulocytopenic patients.
    Rev Infect Dis. 1991 May-Jun;13(3):496-503 PMID: 1866556
  239. A new methionine antagonist that has antifungal activity: mode of action.
    J Antibiot (Tokyo). 1994 Aug;47(8):909-16 PMID: 7928678
  240. How do the polyene macrolide antibiotics affect the cellular membrane properties?
    Biochim Biophys Acta. 1986 Dec 22;864(3-4):257-304 PMID: 3539192
  241. Synergistic action of nikkomycins X and Z with papulacandin B on whole cells and regenerating protoplasts of Candida albicans.
    Antimicrob Agents Chemother. 1986 Mar;29(3):389-94 PMID: 3521483
  242. Increased sensitivity of Candida albicans cells accumulating 14 alpha-methylated sterols to active oxygen: possible relevance to in vivo efficacies of azole antifungal agents.
    Antimicrob Agents Chemother. 1992 Aug;36(8):1626-9 PMID: 1329623
  243. Pradimicins A, B and C: new antifungal antibiotics. II. In vitro and in vivo biological activities.
    J Antibiot (Tokyo). 1990 Jul;43(7):763-70 PMID: 2167304
  244. Both isoforms of protein phosphatase Z are essential for the maintenance of cell size and integrity in Saccharomyces cerevisiae in response to osmotic stress.
    Eur J Biochem. 1993 Aug 15;216(1):269-79 PMID: 8396031
  245. The Wellcome Lecture, 1992. Cell cycle control.
    Philos Trans R Soc Lond B Biol Sci. 1993 Sep 29;341(1298):449-54 PMID: 7902990
  246. Role of cell defense against oxidative damage in the resistance of Candida albicans to the killing effect of amphotericin B.
    Antimicrob Agents Chemother. 1988 May;32(5):702-5 PMID: 3293525
  247. Sphingolipids with inositolphosphate-containing head groups.
    Adv Lipid Res. 1993;26:253-74 PMID: 8379454
  248. Cryptococcal immunity and immunostimulation.
    Adv Exp Med Biol. 1992;319:225-30 PMID: 1414597
  249. Joining the complex: cyclin-dependent kinase inhibitory proteins and the cell cycle.
    Cell. 1994 Oct 21;79(2):181-4 PMID: 7954786
  250. Human mycoses: drugs and targets for emerging pathogens.
    Science. 1994 Apr 15;264(5157):371-3 PMID: 8153622
  251. In vivo effects of fenpropimorph on the yeast Saccharomyces cerevisiae and determination of the molecular basis of the antifungal property.
    Antimicrob Agents Chemother. 1990 Jun;34(6):989-93 PMID: 2203312
  252. Morphological effects of lipopeptides against Aspergillus fumigatus correlate with activities against (1,3)-beta-D-glucan synthase.
    Antimicrob Agents Chemother. 1994 Jul;38(7):1480-9 PMID: 7979276
  253. Biochemical basis for the interactions of type I and type II topoisomerases with DNA.
    Pharmacol Ther. 1989;41(1-2):223-41 PMID: 2540496
  254. Inhibition by the fungicide fenpropimorph of cholesterol biosynthesis in 3T3 fibroblasts.
    Biochem J. 1988 Dec 15;256(3):829-34 PMID: 3223956
  255. Trichosporon beigelii, an emerging pathogen resistant to amphotericin B.
    J Clin Microbiol. 1990 Jul;28(7):1616-22 PMID: 2380383
  256. Antibody-mediated protection in mice with lethal intracerebral Cryptococcus neoformans infection.
    Proc Natl Acad Sci U S A. 1993 Apr 15;90(8):3636-40 PMID: 8475112
  257. Amphotericin B: an introduction.
    J Antimicrob Chemother. 1991 Oct;28 Suppl B:27-38 PMID: 1778890
  258. Role of granulocyte-macrophage colony-stimulating factor as adjuvant therapy for fungal infection in patients with cancer.
    Clin Infect Dis. 1993 Oct;17(4):705-7 PMID: 8268354
  259. Ro 09-1470 is a selective inhibitor of P-450 lanosterol C-14 demethylase of fungi.
    Antimicrob Agents Chemother. 1993 Dec;37(12):2662-7 PMID: 8109933
  260. The iC3b receptor on Candida albicans: subcellular localization and modulation of receptor expression by glucose.
    J Infect Dis. 1990 Apr;161(4):761-8 PMID: 2138655
  261. The use of divalent cations and pH for the determination of specific yeast chitin synthetases.
    Anal Biochem. 1994 Jun;219(2):368-72 PMID: 8080094
  262. Folimycin (concanamycin A), an inhibitor of V-type H(+)-ATPase, blocks cell-surface expression of virus-envelope glycoproteins.
    Biochem Biophys Res Commun. 1993 Jun 30;193(3):999-1005 PMID: 8391816
Article Info
Journal
Antimicrobial agents and chemotherapy
Abbr.
Antimicrob Agents Chemother
ISSN
0066-4804
DOI
10.1128/AAC.40.2.279
Published
1996-02-00
Pages
279-91
Language
English
Region
United States
NLM ID
0315061
PMCID
PMC163103
Subset
IM
External Links
PubMed source DOI: 10.1128/AAC.40.2.279 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2